drugset / Trial / NCT04589351
Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe
Phase 3
Unknown
60 enrolled
Steno Diabetes Center Copenhagen
Aalborg University Hospital · collabAlessia Fornoni, MD PhD, Professor of Medicine, Chief, Katz Family Division of Nephrology and Hypertension · collabCapital Region's Pharmacy (Region Hovedstadens Apotek), Marielundvej 25, 2730 Herlev, Denmark · collabGlostrup University Hospital, Copenhagen · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
In this study, we seek to explore the importance of fat accumulation in the kidneys in relation to diabetic kidney disease (DKD). To do this, we conduct an intervention trial in individuals with type 2 diabetes (T2D) and DKD where we investigate whether the inhibition of intestinal cholesterol absorption with ezetimibe affects albuminuria (a strong risk factor for diabetic complications) and kidney fat accumulation. At the same time and to confirm that kidney fat accumulation is, in fact, abnormal in T2D and DKD, we conduct a cross-sectional study in which we compare kidney fat accumulation in participants at baseline from the intervention trial with a group of individuals with T2D and no DKD and a group of healthy individuals.
Timeline
- Start
- 2020-10-01
- Primary completion
- 2022-05
- Completion
- 2022-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ezetimibe | Unknown | 10 mg | — |